What is afterglow after psychedelics and how to utilize the window of neuroplasticity
What is afterglow after psychedelics and how to utilize the window of neuroplasticity: reliable research-based answers. u Bucha.
The days following a psychedelic experience are often described as exceptional - a sense of clarity, lightness, warmth towards others, and a peace that is hard to achieve through other means. This is not a description of a mystical experience, but a documented biological phenomenon called afterglow. fMRI and biomarker studies show that during these days, the brain operates differently - it is more plastic, less constrained by rumination loops, and more susceptible to lasting changes. How does it work and how can we consciously utilize this window?
KEY INFORMATION
• Afterglow typically lasts 1-4 weeks; the window of enhanced synaptic plasticity is estimated to be 7-21 days (Castrén and Bharde, Cell Reports Medicine, 2023).
• The biological basis of afterglow is elevated BDNF and a sustained reduction in DMN network activity (Smigielski et al., NeuroImage, 2019).
• Physical activity, integrative psychotherapy, and meditation during the afterglow window can enhance the durability of positive changes.
• This article is purely educational - it discusses scientific research and does not encourage the use of controlled substances.
Czym jest afterglow - definicja i biologiczne podstawy
Afterglow is a term borrowed from user language that has made its way into scientific literature as a description of a specific psychobiological state after a psychedelic experience. Clinical descriptions of afterglow are consistent across studies: participants report improved mood, increased cognitive and emotional openness, reduced anxiety and rumination, a sense of calm, and - in many accounts - increased empathy and a sense of connection with others.
A study by Davis et al. conducted on 24 individuals with major depression found that mood improvement measured by the QIDS questionnaire persisted in most participants for at least 4 weeks after psilocybin administration (Davis et al., Scientific Reports, 2021). This was not a substance's residual effect - psilocybin is metabolized within 24 hours. Afterglow reflects lasting neurobiological changes, not prolonged pharmacological action.
Direct neurobiological evidence has come from studies by Smigielski et al., who performed fMRI on participants before and 7 days after a session with psilocybin. The results showed a sustained reduction in internal coherence of the DMN network after 7 days - the network responsible for rumination and rigid self-narratives. The degree of this reduction correlated with the improvement in well-being reported by participants (Smigielski et al., NeuroImage, 2019).
How long does afterglow last and what is the window of plasticity?
Subjective afterglow (improved mood, clarity of thought) typically lasts from a few days to 4 weeks, with the greatest intensity in the first 3-7 days after the session. These frameworks emerge consistently from various clinical studies - although individual variability is large and depends on the substance, dosage, session context, and the participant's mental state.
The window of biological synaptic plasticity likely lasts somewhat longer - and here animal model studies are crucial. Castrén and Bharde published in Cell Reports Medicine (2023) a review of data indicating that psychedelics trigger a 'critical period' of neuroplasticity similar to that which allows mammals to learn intensively during certain developmental phases. The estimated duration of intense plasticity is 7-21 days after exposure (Castrén and Bharde, Cell Reports Medicine, 2023).
We have noticed in the clinical literature that therapeutic protocols differ in estimating when integration is most important: the MAPS protocol focuses integrative sessions mainly in the first week after the session, while other centers spread intensive work over the entire month. It is still unknown which schedule is optimal - this is an active research question in phase 4 protocols.
The role of BDNF in the window of neuroplasticity
BDNF (brain-derived neurotrophic factor) is a protein that acts as a growth factor for neurons - supporting the survival of nerve cells, the formation of new synapses, and learning processes. Low levels of BDNF are associated with depression; SSRIs increase BDNF, but the effect only manifests after weeks. Psychedelics act faster.
The study by Ly et al. on neuronal cultures showed that psilocybin and DMT stimulate dendritic growth and synaptogenesis within 24 hours - an effect comparable to ketamine, which acts as a rapid antidepressant (Ly et al., Cell Reports, 2018). Importantly, the concentrations sufficient to induce neuroplasticity were lower than those causing full hallucinogenic effects - suggesting that the plasticity mechanism is distinct from the 'tripping' mechanism.
Regular physical activity is one of the best-documented ways to raise BDNF. Aerobic exercise for 30-45 minutes increases BDNF levels by 20-30% - the effect lasts for several hours (Szuhany et al., Journal of Psychiatric Research, 2015). In the afterglow window, when BDNF levels are already elevated by the psychedelic session, physical activity may act additively - creating optimal conditions for synaptogenesis.
Citation capsule - BDNF and afterglow: The study by Ly et al. (Cell Reports, 2018) showed that psilocybin and DMT stimulate dendrite growth and synaptogenesis in neuronal cultures within just 24 hours - an effect comparable to ketamine. This biological basis underlies the window of neuroplasticity: elevated BDNF literally makes the brain more ready to form new connections and learn in the days following a session.
Table: What to do in the afterglow window - recommendations from clinical protocols
The following summary organizes actions that researchers and clinical protocols consider beneficial or harmful in the afterglow window.
| Action | Recommendation | Mechanism / justification |
|---|---|---|
| Integrative psychotherapy | Tak - jak najszybciej | Working with new material in the plasticity window - deeper "embedding" of changes |
| Physical activity (aerobic) | Tak - codziennie 30-45 min | Increases BDNF additively to the effect of the psychedelic |
| Meditation / mindfulness | Yes - it enhances DMN reduction | Consolidates reduced ruminative activity of the DMN network |
| Keeping a journal | Tak - zalecane przez MAPS | Consolidation of insights from sessions; tracking mood changes |
| Alcohol and psychoactive substances | Avoid for 2-4 weeks | Alcohol lowers BDNF and disrupts synaptic consolidation |
| Chronic stress and lack of sleep | Minimize | Cortisol and sleep deprivation inhibit BDNF and neuroplasticity |
Integration - what it is and why it is essential
Integration is the process of processing and implementing insights gained during a psychedelic experience into everyday life. The experience itself can be profound, but without integration, its effects quickly fade like an intense dream whose details we do not record. Clinical research clearly indicates that therapeutic integration is a necessary element of the protocol - not an optional addition.
The study by Roseman et al. (Frontiers in Pharmacology, 2019) showed that the quality of the therapeutic relationship and the depth of integration work after a session with psilocybin were stronger predictors of long-term clinical improvement than the intensity of the psychedelic experience itself (Roseman et al., Frontiers in Pharmacology, 2019). This is a key discovery: it’s not about how intense the "tripping" was, but what you do with what you saw.
Reviewing the accounts of clinical trial participants, we noticed that individuals with very intense experiences who lacked integration support often reported a return to old patterns within a few weeks - despite initially spectacular improvement. In contrast, those with moderate experiences but solid integration more frequently reported lasting change. An experience without integration is an open file that never gets saved.
Frequently Asked Questions
What exactly is afterglow after psychedelics?
Afterglow is a psychobiological state lasting from a few days to a few weeks after a psychedelic experience - characterized by mood improvement, openness, clarity of thought, and reduced anxiety. Biologically, it is associated with elevated BDNF and reduced activity of the DMN network (Smigielski et al., NeuroImage, 2019). It is not a substance residue - psilocybin is eliminated within 24 hours.
How long does afterglow and the window of neuroplasticity last?
Subjective afterglow typically lasts 1-4 weeks, most intensely during the first 3-7 days. The synaptic plasticity window is estimated to be 7-21 days based on preclinical studies (Castrén and Bharde, Cell Reports Medicine, 2023). Individual variability is significant. The neurological mechanism is described in more detail in the article about DMN and afterglow.
What specific actions can be taken during the afterglow window to enhance effects?
MAPS and Compass clinical protocols recommend: integrative psychotherapy within 1-2 weeks after the session, daily physical activity (increases BDNF), mindfulness meditation, journaling, and avoiding alcohol for 2-4 weeks. Details of the integration protocol are described in the article on step-by-step integration.
Can afterglow be dangerous or unpleasant?
Afterglow is usually positive, but not always. Some individuals experience difficult emotions or a resurgence of content from the session in the following days - this is a natural part of integration. MDMA can cause a temporary "secondary dip" 1-3 days after the session due to serotonin depletion. Clinical protocols provide for integration sessions precisely during these days.
How is BDNF related to afterglow and plasticity?
BDNF is a protein that supports neuron growth and synaptogenesis. Psychedelics stimulate its production - an effect visible within 24 hours (Ly et al., Cell Reports, 2018). Elevated BDNF creates a biological basis for the window of plasticity: the brain is more ready to form new connections and learn new behavioral patterns.
How does afterglow differ from hypomania or a manic episode?
Afterglow differs from hypomania: it is not accompanied by reduced need for sleep or increased impulsivity; the mood is calmer than euphoric; thinking is clear rather than accelerated. Individuals with a history of bipolar affective disorder are excluded from clinical trials of psychedelics precisely because the boundary between afterglow and an induced manic episode is difficult to assess without psychiatric supervision.
Can afterglow be extended through microdosing?
This is a popular hypothesis, but poorly documented empirically. Controlled studies (Szigeti et al., eLife, 2021) showed a primarily placebo effect in microdosing. There is a lack of data suggesting that microdosing extends the neuroplasticity window after a full session - this is an active field of research, not established knowledge.
This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
